Human papillomavirus 16 L1-E7 chimeric virus like particles show prophylactic and therapeutic efficacy in murine model of cervical cancer

Vaccine

Volumn 30, Issue 36, 2012, Pages 5417-5424

  Sharma, Chandresh ^a   Dey, Bindu ^b   Wahiduzzaman, Mohammed ^a   Singh, Neeta ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b Government of India   (India)

Author keywords

Chimeric vaccine; CVLP vaccine; HPV vaccine; HPV16 vaccine

Indexed keywords

ANTIVIRUS AGENT; NEUTRALIZING ANTIBODY; RECOMBINANT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELLULAR IMMUNITY; CHIMERA; CONTROLLED STUDY; ESCHERICHIA COLI; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNE RESPONSE; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; UTERINE CERVIX CANCER; VIRUS PARTICLE; VIRUS RECOMBINANT;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CAPSID PROTEINS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; CYTOTOXICITY, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; EPITOPES, T-LYMPHOCYTE; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; IMMUNITY, HUMORAL; IMMUNOGLOBULIN ISOTYPES; INTERFERON-GAMMA; MICE; MICE, INBRED C57BL; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS INFECTIONS; RECOMBINANT FUSION PROTEINS; TH1 CELLS; UTERINE CERVICAL NEOPLASMS; VACCINES, VIRUS-LIKE PARTICLE;

EID: 84863999429     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.06.010     Document Type: Article

References (42)

1. Bosch F.X., Munoz N. The viral etiology of cervical cancer. Virus Res 2002, 89(2):183-190.
2. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002, 2(5):342-350.
3. Parkin D.M., Bray F. Chapter 2: the burden of HPV-related cancers. Vaccine 2006, 24(Suppl. 3). S3/11-S3/25.
4. Frazer I.H., Quinn M., Nicklin J.L., Tan J., Perrin L.C., Ng P., et al. Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasia. Vaccine 2004, 23(2):172-181.
5. Kirnbauer R., Taub J., Greenstone H., Roden R., Durst M., Gissmann L., et al. Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J Virol 1993, 67(12):6929-6936.
6. Suzich J.A., Ghim S.J., Palmer-Hill F.J., White W.I., Tamura J.K., Bell J.A., et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci USA 1995, 92(25):11553-11557.
7. De Bruijn M.L., Greenstone H.L., Vermeulen H., Melief C.J., Lowy D.R., Schiller J.T., et al. L1-specific protection from tumor challenge elicited by HPV16 virus-like particles. Virology 1998, 250(2):371-376.
8. Bosch F.X., de Sanjose S. Human papillomavirus in cervical cancer. Curr Oncol Rep 2002, 4(2):175-183.
9. Agosti J.M., Goldie S.J. Introducing HPV, vaccine in developing countries-key challenges and issues. N Engl J Med 2007, 356(19):1908-1910.
10. van der Burg S.H., de Jong A., Welters M.J., Offringa R., Melief C.J. The status of HPV16-specific T-cell reactivity in health and disease as a guide to HPV vaccine development. Virus Res 2002, 89(2):275-284.
11. Nakagawa M., Stites D.P., Farhat S., Sisler J.R., Moss B., Kong F., et al. Cytotoxic T lymphocyte responses to E6 and E7 proteins of human papillomavirus type 16: relationship to cervical intraepithelial neoplasia. J Infect Dis 1997, 175(4):927-931.
12. Schafer K., Muller M., Faath S., Henn A., Osen W., Zentgraf H., et al. Immune response to human papillomavirus 16 L1E7 chimeric virus-like particles: induction of cytotoxic T cells and specific tumor protection. Int J Cancer 1999, 81(6):881-888.
13. Peng S., Frazer I.H., Fernando G.J., Zhou J. Papillomavirus virus-like particles can deliver defined CTL epitopes to the MHC class I pathway. Virology 1998, 240(1):147-157.
14. Greenstone H.L., Nieland J.D., de Visser K.E., De Bruijn M.L., Kirnbauer R., Roden R.B., et al. Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model. Proc Natl Acad Sci USA 1998, 95(4):1800-1805.
15. Liu W.J., Liu X.S., Zhao K.N., Leggatt G.R., Frazer I.H. Papillomavirus virus-like particles for the delivery of multiple cytotoxic T cell epitopes. Virology 2000, 273(2):374-382.
16. Liu X.S., Liu W.J., Zhao K.N., Liu Y.H., Leggatt G., Frazer I.H. Route of administration of chimeric BPV1 VLP determines the character of the induced immune responses. Immunol Cell Biol 2002, 80(1):21-29.
17. Varsani A., Williamson A.L., de Villiers D., Becker I., Christensen N.D., Rybicki E.P. Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16. J Virol 2003, 77(15):8386-8393.
18. Muller M., Zhou J., Reed T.D., Rittmuller C., Burger A., Gabelsberger J., et al. Chimeric papillomavirus-like particles. Virology 1997, 234(1):93-111.
19. Kaufmann A.M., Nieland J., Schinz M., Nonn M., Gabelsberger J., Meissner H., et al. HPV16 L1E7 chimeric virus-like particles induce specific HLA-restricted T cells in humans after in vitro vaccination. Int J Cancer 2001, 92(2):285-293.
20. Picconi M.A., Alonio L.V., Garcia Carranca A., Lizano M., Cervantes Vazquez G., Distefano A.L., et al. Molecular variants of human papillomavirus (HPV) types 16 and 18 in adenocarcinomas of the cervix. Medicina (B Aires) 2000, 60(6):889-894.
21. Varsani A., Williamson A.L., Jaffer M.A., Rybicki E.P. A deletion and point mutation study of the human papillomavirus type 16 major capsid gene. Virus Res 2006, 122(1-2):154-163.
22. Pillai M.R., Hariharan R., Babu J.M., Lakshmi S., Chiplunkar S.V., Patkar M., et al. Molecular variants of HPV-16 associated with cervical cancer in Indian population. Int J Cancer 2009, 125(1):91-103.
23. Bian T., Wang Y., Lu Z., Ye Z., Zhao L., Ren J., et al. Human papillomavirus type 16 L1E7 chimeric capsomeres have prophylactic and therapeutic efficacy against papillomavirus in mice. Mol Cancer Ther 2008, 7(5):1329-1335.
24. Roden R.B., Hubbert N.L., Kirnbauer R., Breitburd F., Lowy D.R., Schiller J.T. Papillomavirus L1 capsids agglutinate mouse erythrocytes through a proteinaceous receptor. J Virol 1995, 69(8):5147-5151.
25. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983, 65(1-2):55-63.
26. Feltkamp M.C., Smits H.L., Vierboom M.P., Minnaar R.P., de Jongh B.M., Drijfhout J.W., et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 1993, 23(9):2242-2249.
27. Ohlschlager P., Osen W., Dell K., Faath S., Garcea R.L., Jochmus I., et al. Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice. J Virol 2003, 77(8):4635-4645.
28. Decker T., Lohmann-Matthes M.L. A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity. J Immunol Methods 1988, 115(1):61-69.
29. Kjaer S.K., Sigurdsson K., Iversen O.E., Hernandez-Avila M., Wheeler C.M., Perez G., et al. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila) 2009, 2(10):868-878.
30. Olsson S.E., Kjaer S.K., Sigurdsson K., Iversen O.E., Hernandez-Avila M., Wheeler C.M., et al. Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum Vaccine 2009, 5(10):696-704.
31. Paavonen J., Naud P., Salmeron J., Wheeler C.M., Chow S.N., Apter D., et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009, 374(9686):301-314.
32. Kaufmann A.M., Nieland J.D., Jochmus I., Baur S., Friese K., Gabelsberger J., et al. Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3). Int J Cancer 2007, 121(12):2794-2800.
33. Chen X.S., Garcea R.L., Goldberg I., Casini G., Harrison S.C. Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16. Mol Cell 2000, 5(3):557-567.
34. Li H., Nookala S., Re F. Aluminum hydroxide adjuvants activate caspase-1 and induce IL-1beta and IL-18 release. J Immunol 2007, 178(8):5271-5276.
35. Carter J.J., Koutsky L.A., Hughes J.P., Lee S.K., Kuypers J., Kiviat N., et al. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis 2000, 181(6):1911-1919.
36. Bontkes H.J., de Gruijl T.D., Walboomers J.M., van den Muysenberg A.J., Gunther A.W., Scheper R.J., et al. Assessment of cytotoxic T-lymphocyte phenotype using the specific markers granzyme B and TIA-1 in cervical neoplastic lesions. Br J Cancer 1997, 76(10):1353-1360.
37. Matsumoto K., Leggatt G.R., Zhong J., Liu X., de Kluyver R.L., Peters T., et al. Impaired antigen presentation and effectiveness of combined active/passive immunotherapy for epithelial tumors. J Natl Cancer Inst 2004, 96(21):1611-1619.
38. Chen L.P., Thomas E.K., Hu S.L., Hellstrom I., Hellstrom K.E. Human papillomavirus type 16 nucleoprotein E7 is a tumor rejection antigen. Proc Natl Acad Sci USA 1991, 88(1):110-114.
39. Chen C.H., Wang T.L., Hung C.F., Pardoll D.M., Wu T.C. Boosting with recombinant vaccinia increases HPV-16 E7-specific T cell precursor frequencies of HPV-16 E7-expressing DNA vaccines. Vaccine 2000, 18(19):2015-2022.
40. Dupuy C., Buzoni-Gatel D., Touze A., Le Cann P., Bout D., Coursaget P. Cell mediated immunity induced in mice by HPV 16 L1 virus-like particles. Microb Pathog 1997, 22(4):219-225.
41. Nakagawa M., Stites D.P., Palefsky J.M., Kneass Z., Moscicki A.B. CD4-positive and CD8-positive cytotoxic T lymphocytes contribute to human papillomavirus type 16 E6 and E7 responses. Clin Diagn Lab Immunol 1999, 6(4):494-498.
42. Liu X.S., Leerberg J., MacDonald K., Leggatt G.R., Frazer I.H. IFN-gamma promotes generation of IL-10 secreting CD4+ T cells that suppress generation of CD8 responses in an antigen-experienced host. J Immunol 2009, 183(1):51-58.